PMG
ANIP icon

ProVise Management Group’s ANI Pharmaceuticals ANIP Stock Holding History

ProVise Management Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-6,000
Closed -$202K – 303
2016
Q1 		$202K Hold
6,000
– – 0.04% 269
2015
Q4 		$271K Buy
+6,000
New +$258K 0.06% 236

Other funds holding ANIP

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

ProVise Management Group's ANIP Position: Q2 2016 in Review

ProVise Management Group sold out of ANI Pharmaceuticals (ANIP) in Q2 2016, closing a stake of 6,000 shares — an estimated $202K sold.

ProVise Management Group first reported a position in ANIP in Q4 2015 and held it in 2 quarters. The position peaked at $271K in Q4 2015. 138 funds tracked by Wall St. Rank hold ANIP as of Q2 2016.

  • ProVise Management Group reported no remaining ANI Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • ProVise Management Group sold 6,000 ANI Pharmaceuticals shares in Q2 2016, an estimated $202K.
  • ProVise Management Group first reported a position in ANI Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • ProVise Management Group's ANI Pharmaceuticals position peaked at $271K in Q4 2015.
  • 138 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2016.

Based on ProVise Management Group's 13F filing for Q2 2016, filed 2 Aug 2016.